- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Diasome Pharmaceuticals, a clinical stage diabetes therapeutics company, today announced that its abstract was selected for presentation at the 69th Scientific Sessions of the American Diabetes Association (ADA), being held June 5-9 at the Morial Convention Center in New Orleans, La. The ADA is the nation's premier voluntary health organization supporting diabetes research, information and advocacy.
Diasome Pharmaceutical's poster presentation will be focusing on the administration of Oral HDV-Insulin in a food-dose timing trial. The following abstract will be presented as a poster from Saturday, June 6 through Monday, June 8 in the Morial Convention Center's Hall D and Hall E:
A Single-Blind, Placebo-Controlled, Food-Dose Timing Trial of Oral HDV-Insulin in Patients with Type 2 Diabetes Mellitus. Blair Geho, MD, PhD, John Lau, Len Rosenberg, PhD, RPh, Sherwyn Schwartz, MD. Diasome Pharmaceuticals, Conshohocken, PA and Diabetes Glandular Research Center, San Antonio, TX.
Diasome's Oral HDV-Insulin is a nanotechnology-based cell targeting system for the improved treatment of diabetes mellitus. This drug delivery system is specifically targeted to hepatocytes, the primary metabolic cells in the liver. Diasome's therapies have been tested in more than 250 subjects through Phase II studies, and have shown the ability to lower blood glucose levels in diabetics.
About Diasome Pharmaceuticals
Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company focused on novel insulin-based therapies for the improved treatment of diabetes. The Company was formed in late 2004 and has completed multiple Phase II human studies of HDV-Insulin, its proprietary insulin targeting system. Diasome uses a unique, nano-technology based cell targeting system to preferentially deliver insulin to the hepatocytes in the liver. This technology has led to the development of Oral HDV-Insulin, an advanced oral delivery system for insulin. For more information, please visit Diasome’s website at www.diasome.com.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The Association's commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. www.diabetes.org
For more information, please click here
Copyright © BusinessWireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Iran Unveils 6 Knowledge-Based Products April 11th, 2015
DELSEY by Philippe Starck DELSEY Launches New Collection by Philippe Starck February 4th, 2015
NEI introduces NANOMYTE® SuperAi, a Durable Anti-ice Coating December 4th, 2014
Richards-Kortum elected to American Academy of Arts and Sciences: April 22nd, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Rafts on the cell membrane: Researchers from TU Wien (Vienna) shed light on a big secret of cell membranes: The 'lipid rafts', which have been believed to move within the cell membrane, do not really exist April 21st, 2015